Zephyrm Bioscience, a Chinese stem-cell drug developer, is seeking an IPO on the Hong Kong Stock Exchange amidst a surge in losses and a buoyant market. The company, known for its innovative cell therapy products, is hoping to raise funds to support its R&D efforts and upcoming commercialization, but its financial performance raises concerns.